≪英文≫

GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer.

Tanegashima T, Shiota M, Doi A, Tatarano S, Kamba T, Igawa T, Masumori N, Uemura H, Kamoto T, Higashijima K, Mitsunari K, Uemura H, Sumiyoshi T, Isoda T, Ishigami K, Toskunaga S, Eto M.

EJNMMI Res. 2026 Jun 2. doi: 10.1186/s13550-026-01463-3. Online ahead of print. PMID: 42230449

 

The Cyclin C-CDK8/19 Mediator kinase module controls PRCC-TFE3 driven senescence in renal epithelium and tumorigenesis in TFE3-RCC.

Kuroda S, Funasaki S, Nishizawa H, Schmidt LS, Kurahashi R, Ito T, Arima Y, Tanaka M, Kitada A, James AM, Hasumi H, Jikuya R, Makiyama K, Kurotaki D, Minami T, Difilippantonio S, Linehan WM, Oike Y, Sawa T, Tanaka Y, Suda T, Yokokawa R, Nakamura T, Baba M, Kamba T.

Neoplasia. 2026 May;75:101296. doi: 10.1016/j.neo.2026.101296. Epub 2026 Mar 16. PMID: 41843980

 

Impact of treatment volume on outcomes for patients with penile cancer at relatively low-volume centers in Japan.

Murakami Y, Yamaguchi T, Goya M, Higashijima K, Tobu S, Sato R, Tatarano S, Mukai S, Uemura KI, Tatsugami K, Tsubouchi K, Shida Y, Ishii T, Sakai H, Matsuoka H, Haga N, Eto M, Igawa T, Kamoto T, Enokida H, Shin T, Noguchi M, Fujimoto N, Saito S, Kamba T.

Jpn J Clin Oncol. 2026 Apr 30:hyag070. doi: 10.1093/jjco/hyag070. Online ahead of print. PMID: 42059484

 

Comprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer.

Sano T, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Kato M, Sazuka T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kobayashi T; Japan Urological Oncology Group.

Sci Rep. 2026 Apr 5. doi: 10.1038/s41598-026-46649-w. Online ahead of print. PMID: 41936674

 

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.

Choueiri TK, Motzer RJ, Karam JA, Yip W, Suarez C, Ye D, He Z, Caglevic C, Ferguson T, Chang YH, Rojas C, Iacovelli R, Urun Y, Verzoni E, Vazquez Limon JC, Porta C, Uzzo RG, Lee JL, Venugopal B, McKay RR, Hammers H, Miyake H, Chahoud J, Liu H, Burgents JE, Sharma M, Powles TB; LITESPARK-022 Investigators.

(Yatsuda J is also listed in LITESPARK Investigators in the Supplementary Appendix.)

N Engl J Med. 2026;395(1):32-43.

 

Circulating Tumor DNA Genomic Profiling in ²²³Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study.

Shiota M, Fujiwara M, Sumiyoshi T, Enokida H, Kamba T, Igawa T, Masumori N, Uemura H, Kamoto T, Higashijima K, Mitsunari K, Uemura H, Kobayashi T, Akamatsu S, Tokunaga S, Isoda T, Ishigami K, Eto M.

J Nucl Med. 2026;67(7):1070-1078.

 

Applying classification of intraoperative adverse events (ClassIntra) to robot-assisted radical prostatectomy to predict the risk of postoperative adverse events.

Somiya S, Saito R, Kanno T, Kubota M, Sumiyoshi T, Imamura M, Sugiyama K, Tamaki M, Fukui T, Iwamura H, Suzuki R, Shimatani K, Sekine Y, Kurahashi R, Sawada A, Negoro H, Akamatsu S, Goto T, Kobayashi T; Daimonji Clinical Application Database (Dai-CAD) study group.

(Kamba T is also indicated in Acknowledgement.)

World J Urol. 2026 Jun 2;44(1):402.

 

Younger Age Is Associated With Early Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy.

Hagimoto H, Kubota M, Mizuno K, Sumiyoshi T, Masui K, Matsui Y, Saito R, Fukuzawa S, Shimizu Y, Yoshida T, Akao T, Segawa T, Shimatani K, Sekine Y, Kurahashi R, Sawada A, Negoro H, Akamatsu S, Kobayashi T, Goto T; Daimonji Clinical Application Database (Dai-CAD).

Int J Urol. 2026 Jun;33(6):e70535.

 

Clear Cell Renal Cell Carcinoma With Syncytial Giant Cells: A Case Report With Morphological and Immune-microenvironmental Characterization.

Ozaki Y, Imafuji J, Uekawa A, Ibe Y, Zhao S, Yamada R, Nakamura K, Murakami Y, Yatsuda J, Beppu T, Komohara Y, Kamba T.

Anticancer Res. 2026;46(6):3523-3531.

 

Impact of radium-223 on bone imaging and biochemical markers with and without bone-modifying agents in bone-metastatic castration-resistant prostate cancer: results from the kyucog-1901 study.

Shiota M, Enokida H, Murakami Y, Kamoto T, Igawa T, Masumori N, Uemura H, Mitsunari K, Sumiyoshi T, Uemura H, Higashijima K, Tokunaga S, Isoda T, Ishigami K, Eto M.

Eur J Nucl Med Mol Imaging. 2026;53(7):4436-4445.

 

Avelumab maintenance therapy for advanced urothelial carcinoma: subgroup analyses by characteristics of first-line platinum-based chemotherapy from a real-world chart review study in Japan (JAVEMACS).

Endo Y, Kitamura H, Shirotake S, Ikeda M, Yonemori K, Kawamura N, Fujihara A, Shimizu F, Fujimoto K, Nakagawa T, Hatakeyama S, Nishihara K, Ikarashi D, Masumori N, Naito S, Fujita K, Hara T, Miura N, Negishi T, Yatsuda J, Kobayashi M, Taoka R, Furukawa J, Shono M, Kobayashi T, Kikuchi E.

BMC Cancer. 2026;26(1):575.

 

Biopsy Gleason score 5 + 4 predicts worse outcomes than 4 + 5 after robot-assisted radical prostatectomy: a nationwide multicenter cohort study.

Shimatani K, Kubota M, Yamamoto S, Mizuno K, Sumiyoshi T, Saito R, Ueda M, Iguchi R, Takahashi T, Yokozeki H, Iwamura H, Kohei N, Kurahashi R, Sekine Y, Sawada A, Negoro H, Akamatsu S, Kobayashi T, Goto T.

World J Urol. 2026;44(1):310.

 

Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan.

Kawai T, Miki J, Taoka R, Saito R, Fukuokaya W, Matsui Y, Fujii Y, Hatakeyama S, Kawahara T, Matsuda A, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Nakayama M, Matsumoto T, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Kobayashi K, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kume H; Japan Urological Oncology Group.

Jpn J Clin Oncol. 2026;56(4):475-483.

 

Genetically engineered human iPS cell-derived kidney organoid recapitulates an early stage of ALK fusion gene-associated renal tumorigenesis.

Noguchi G, Baba M, Ohtake S, Jikuya R, Mitome T, Kawamura S, Aomori K, Iribe Y, Nagasaka H, Wilan K, Funasaki S, Muraoka E, Fujii S, Tsuzuki T, Kato I, Furuya M, Nagashima Y, Nishizawa H, Kamba T, Kuraoka S, Kawagoe T, Mizuki N, Tatenuma T, Ueno D, Kawahara T, Ito H, Komeya M, Ito Y, Muraoka K, Uemura H, Tamura T, Ogawa T, Suda T, Yao M, Makiyama K, Nakagawa H, Shuch BM, Ricketts CJ, Schmidt LS, Linehan WM, Nishinakamura R, Hasumi H.

Mol Cancer Res. 2026;24(4):221-231.

 

Longitudinal Impact of Urinary Diversion on Health-Related Quality of Life After Radical Cystectomy: A Multicenter Study in Japan.

Yamada S, Sato M, Osawa T, Harabayashi T, Miki J, Kobayashi T, Hashine K, Kawashima A, Matsumoto T, Mochizuki T, Taoka R, Urabe F, Tatarano S, Sawada A, Kojima T, Takahashi A, Yokomizo A, Suekane S, Hashimoto K, Hashimoto Y, Yatsuda J, Morita K, Kobayashi K, Satake Y, Sazawa A, Matsui Y, Ito YM, Shimizu S, Fukuhara S, Nishiyama H, Kitamura H, Shinohara N; Japanese Urological Oncology Group.

Cancer Sci. 2026;117(3):739-748.

 

Effectiveness and Safety of Radium-223 for Bone-Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study.

Shiota M, Tatarano S, Kamba T, Kamaoto T, Igawa T, Masumori N, Uemura H, Mitsunari K, Sumiyoshi T, Uemura H, Higashijima K, Tokunaga S, Eto M.

Cancer Sci. 2026;117(2):501-510.

 

Validation of the 7-Item Quality of Life Disease-Specific Impact Scale in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Cross-Sectional Study.

Shimizu S, Osawa T, Sato M, Yamada S, Harabayashi T, Miki J, Kobayashi T, Hashine K, Kawashima A, Matsumoto T, Mochizuki T, Taoka R, Urabe F, Tatarano S, Sawada A, Kojima T, Takahashi A, Yokomizo A, Suekane S, Hashimoto K, Hashimoto Y, Yatsuda J, Morita K, Kobayashi K, Satake Y, Sazawa A, Matsui Y, Ito YM, Nishiyama H, Kitamura H, Shinohara N, Fukuhara S; Japanese Urological Oncology Group.

Int J Urol. 2026;33(2):e70364.

 

Comparison of first-line immuno-oncology combinations with molecular targeted therapy in patients with advanced renal cell carcinoma undergoing hemodialysis: a real-world multicenter retrospective study.

Ueda K, Kurata H, Murakami Y, Minato A, Shiota M, Nakanishi S, Kiyoshima K, Inoue T, Kumagae H, Irie S, Noguchi M, Tatarano S, Matsuzaki H, Tokuda Y, Sawada A, Abe T, Oshiro Y, Harada S, Igawa T.

Int J Clin Oncol. 2026;31(1):160-171.

 

Comprehensive Histopathological and Biochemical Analyzes of Prostatic Amyloid Bodies (Corpora Amylacea) From Autopsy Samples From Japanese Patients.

Yatsuda J, Kanenawa K, Nomura T, Okada M, Masuda T, Misumi Y, Tasaki M, Ueda M, Ando Y, Kamba T.

Prostate. 2026;86(1):116-123.

 

 

≪和文≫

進行性腎細胞癌に対するHIF-2α阻害薬を含む新規薬剤とその役割

穴見俊樹，神波大己

西日泌尿. 2026;88(4):285-286. (Proceedings)